CollPlant Biotechnologies and Stratasys Ltd have embarked on a pre-clinical study, introducing 200cc regenerative implants printed on a unique Stratasys Origin 3D printer, poised to revolutionize breast augmentation.
This pivotal study aims to explore the implants’ potential to foster natural breast tissue growth and biodegrade effortlessly. A fusion of CollPlant’s rhCollagen-based bioinks and Stratasys’ cutting-edge technology, the study represents a significant leap towards offering patients regenerative medicine options over traditional implants.
Delving Deeper into the Collaboration
CollPlant, an innovator in regenerative and aesthetic medicine, synergizes its expertise in rhCollagen for tissue regeneration with Stratasys, a prominent player in polymer 3D printing solutions. Stratasys has engineered the Origin printer to craft these groundbreaking implants, following their collaboration announcement in April 2023. Anticipated initial results from the study are expected by the first half of 2025.
The joint effort envisions a bioprinting breakthrough for CollPlant’s regenerative breast implants, aiming to streamline the implant manufacturing process. These implants are engineered to stimulate natural breast tissue formation and eventually disintegrate entirely, promising a paradigm shift in reconstructive and cosmetic procedures.
Market Potential and Industry Landscape
According to The Brainy Insights, the global breast implant market is valued at $3 billion, with breast augmentation and reconstruction among the most prevalent plastic surgery procedures worldwide. Traditional procedures utilize synthetic breast implants made of silicone, lacking the regenerative potential of natural tissue and potentially posing risks of complications.
Price Performance Analysis
Year-to-date, CLGN shares have incurred a 24.1% decrease, contrasting with the industry’s marginal 0.2% ascent. Over the same period, the S&P 500 has demonstrated a robust 17.7% upturn.
Image Source: Zacks Investment Research
Zacks Rank & Promising Stock Options
CLGN presently holds a Zacks Rank #3 (Hold).
Notable stocks in the broader medical sector include Universal Health Service and ABM Industries. Universal Health Service carries a Zacks Rank #1 (Strong Buy), while ABM Industries boasts a Zacks Rank #2 (Buy).
Universal Health Service exhibits an estimated long-term growth rate of 19% and consistently outperforms earnings expectations. Meanwhile, ABM Industries has exceeded earnings estimates over the last four quarters, portraying an average surprise of 7.34%.
Year-to-date, Universal Health Service has surged by 41.1%, surpassing the industry’s 34.8% growth. Likewise, ABM Industries has climbed 24.1% in the same timeframe, eclipsing the industry’s 11.9% uptick.